Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.57 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Visualizing the World’s Biggest Pharmaceutical Companies ↗

September 17, 2021

Some of the world’s biggest pharmaceutical companies have played a central role in the COVID-19 pandemic.

Via Talk Markets

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

Look For The Q4 Biotech Bounce In Mid-Small Caps ↗

September 17, 2021

Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best...

Via Talk Markets

Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know ↗

September 15, 2021

Biogen Inc's (NASDAQ: BIIB) Spinraza (nusinersen), spinal muscular atrophy (SMA) drug launched in early 2017, faces new competition from Roche Holdings AG's...

Via Benzinga

Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer ↗

September 14, 2021

Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating...

Via Benzinga

These OTCQX & OTCQB Securities Had the Most Trading Activity in August ↗

September 13, 2021

Photo by Javier Allegue Barros on Unsplash August saw a slight increase in trading volume on the OTC Markets with activity showing signs of direction coming out of the summer...

Via Benzinga

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout ↗

September 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...

Via Benzinga

Sunday Special ↗

September 12, 2021

I have a taste for nuclear electricity which France pioneered decades ago, building power stations along the Loire Valley and in other regions. So I took my taste for uranium into my US holdings.

Via Talk Markets

Topics Energy

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs ↗

September 12, 2021

Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest...

Via Benzinga

Why MacroGenics Soared Nearly 9% Higher Today ↗

September 09, 2021

Investors are signaling hope in the company's top drug, despite a disappointing final analysis.

Via The Motley Fool

Delta Variant Fears Continue ↗

September 09, 2021

The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher.

Via Talk Markets

Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition ↗

September 09, 2021

Roche Holdings AG (OTC: RHHBY) has agreed to acquire TIB Molbiol Group for an undisclosed amount. The deal is expected to close in Q4 of 2021. The...

Via Benzinga

MacroGenics Stock Dives As Cancer Drug Shows Mixed Results Vs. Roche Blockbuster ↗

September 08, 2021

A fully approved breast cancer drug from MacroGenics failed to pass muster in a final analysis, and MGNX stock dipped Wednesday.

Via Investor's Business Daily

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis ↗

September 08, 2021

MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast...

Via Benzinga

Why Adaptimmune Therapeutics Stock Is Bolting Higher Today ↗

September 07, 2021

A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.

Via The Motley Fool

Adaptimmune Stock Moves Higher On Cancer Deal With Genentech ↗

September 07, 2021

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC:...

Via Benzinga

Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy ↗

September 07, 2021

Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD). Spark...

Via Benzinga

Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers

September 07, 2021

From Genentech

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ↗

August 31, 2021

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New...

Via Benzinga

Why A Roche-Partnered Alzheimer's Drug Sent AC Immune Stock Flying ↗

August 31, 2021

AC Immune said Tuesday its drug slowed cognitive decline in Alzheimer's patients in a test, and ACIU stock rocketed to a six-month high.

Via Investor's Business Daily

See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate ↗

August 31, 2021

AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase...

Via Benzinga

After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US ↗

August 27, 2021

Following a consultation from the FDA, Roche Holdings AG (OTC: RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type of...

Via Benzinga

Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

August 27, 2021

From Genentech

Via Business Wire

Shape Therapeutics, Roche Form $3B RNA Editing Collaboration ↗

August 24, 2021

Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC: RHHBY) for RNA editing technology....

Via Benzinga

UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗

August 20, 2021

The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent...

Via Benzinga

Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage ↗

August 17, 2021

Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after...

Via Benzinga

AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer ↗

August 09, 2021

AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3...

Via Benzinga

Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients ↗

August 09, 2021

Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously...

Via Benzinga

Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care

August 09, 2021

From Genentech

Via Business Wire

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.